Inogen Secures the US FDA’s Clearance for SIMEOX 200 Airway Clearance Device
Shots:
- The US FDA has granted 510(k) clearance to the SIMEOX 200 Airway Clearance Device for patients with chronic respiratory diseases across the US. A limited launch of the device is planned for 2025 at targeted sites
- SIMEOX 200 is a next-gen. airway clearance device designed to improve bronchial drainage by mobilizing secretions through high-frequency oscillatory vibrations and intermittent negative pressure during exhalation
- The device is intended for patients with chronic lung diseases associated with mucus hypersecretion & retention, such as Bronchiectasis, Chronic Obstructive Pulmonary Diseases (COPD), Cystic Fibrosis or Primary Ciliary Dyskinesia
Ref: Inogen | Image: Inogen
Related News:- MedMira’s Multiplo(R) Rapid (TP/HIV) Test Secures the Health Canada’s Approval for Syphilis and HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
